In an enlightening precedential opinion, the Court of Appeals for the Federal Circuit vacated an infringement judgement against Mylan, a significant decision in the case Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 2022-1889, Fed. Cir. Nov. 6, 2023. In specific, this court judgment engages with Abbreviated New Drug Application (ANDA) litigation, making it particularly relevant to many legal professionals focusing on patent law in the pharmaceutical sector.
The crux of this litigation involved Actelion’s patents related to epoprostenol formulations, which provide coverage for Actelion’s brand-name product, Veletri®. This injectable drug plays a crucial role in the treatment of severe pulmonary arterial hypertension, therefore making any court decisions concerning its patent law particularly impactful on patients, healthcare providers, and the pharmaceutical industry at large.
What sets this case apart from other ANDA litigations is the focus on extrinsic evidence in claim construction. The Federal Circuit ruled that such evidence should have been considered when constructing claims – a notion that strongly contradicts the approach taken by the District Court. This point of the legal dispute may have wider implications for future ANDA litigation and general patent law practices, as it challenges usual approaches towards claim construction.
Understanding the implications of this precedential opinion not only contributes to future ANDA litigation cases, but it also gives us insight into the current trend of increasing complexity in patent lawsuits in the pharmaceutical area. The opinions from such lawsuits often results in significant changes to the interpretation of the law and revisions of existing lawsuit strategies within corporates and law firms.
For more detailed information and a comprehensive view of this case, visit the complete court document.